Search NovaTechs

NovaSeal™
Interventional Radiology
Embolization

Our Product

Novel embolic solutions for interventional radiology

NovaSeal™ - Our flagship product

NovaSeal™

Innovative Liquid Embolic Agent

NovaSeal™ is packaged as a ready-to-use product, eliminating the need for complex and time-consuming preparation steps in hospitals.

Unlike marketed products that rely on heavy metals like tantalum, which pose toxicity risks, NovaSeal™ provides a safer alternative. By avoiding toxic solvents and enhancing ease of use, NovaSeal™ significantly improves the experience for both patients and healthcare providers.

How it works:

NovaSeal™ is a liquid embolic agent composed of a biocompatible polymer mixture and loaded with a contrast agent that transitions from a liquid to a gel state at body temperature. Packaged in a sterile syringe with a standard Luer lock tip, it is injected into a target vessel via intravascular catheters. Upon injection, NovaSeal™ forms a hydrogel embolus, creating a mechanical barrier that occludes blood flow.

NovaSeal™ Benefits

More efficient

Safer

Ready to use

Research & Development

Ongoing projects and clinical trials

Current Status

2023: NovaSeal born

2024: Proof of concept

2025-2026: Verification

2027-2029: Validation

We have completed the in vitro studies. Our team is now focused on designing the preclinical studies, which will pave the way for further verification of NovaSeal™'s safety and efficacy. Following this, we will lay the groundwork for first-in-human trials and prepare for our entry into the global market.

Proof of concept (completed)

Bench Confirmation (completed)

Preclinical Assessment (Ongoing)

Clinical Validation (Design in motion)

2023

NovaSeal born

2024

Proof of concept

2025-2026

Verification

2027-2029

Validation